Saltar al contenido
Merck
Todas las fotos(7)

Documentos clave

HPA029981

Sigma-Aldrich

Anti-SMARCA2 antibody produced in rabbit

enhanced validation

Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution

Sinónimos:

Anti-BAF190, Anti-BRM, Anti-SNF2, Anti-SNF2L2, Anti-SNF2LA, Anti-SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2, Anti-SWI2, Anti-Sth1p, Anti-hBRM, Anti-hSNF2a

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Número MDL:
Código UNSPSC:
12352203
Atlas de proteínas humanas número:
NACRES:
NA.41
En este momento no podemos mostrarle ni los precios ni la disponibilidad

origen biológico

rabbit

Nivel de calidad

conjugado

unconjugated

forma del anticuerpo

affinity isolated antibody

tipo de anticuerpo

primary antibodies

clon

polyclonal

Línea del producto

Prestige Antibodies® Powered by Atlas Antibodies

Formulario

buffered aqueous glycerol solution

reactividad de especies

human

validación mejorada

orthogonal RNAseq
Learn more about Antibody Enhanced Validation

técnicas

immunofluorescence: 0.25-2 μg/mL
immunohistochemistry: 1:500-1:1000

secuencia del inmunógeno

SPVQLHQLRAQILAYKMLARGQPLPETLQLAVQGKRTLPGLQQQQQQQQQQQQQQQQQQQQQQQPQQQPPQPQTQQQQQPALVNYNRPSGPGPELSGPSTPQKLPVP

Nº de acceso UniProt

Condiciones de envío

wet ice

temp. de almacenamiento

−20°C

modificación del objetivo postraduccional

unmodified

Información sobre el gen

human ... SMARCA2(6595)

Descripción general

SMARCA2 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 2) gene is mapped in human chromosome 9p24.3. SMARCA2 is also known as BRM(Brahma) and is an important catalytic component of the SWI/SNF (switch sucrose nonfermentable) chromatin remodeling complex.

Inmunógeno

SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 recombinant protein epitope signature tag (PrEST)

Aplicación

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information.
Anti-SMARCA2 antibody produced in rabbit has been used in immunohistochemistry.

Acciones bioquímicas o fisiológicas

The components of SWI/SNF (switch sucrose nonfermentable) chromatin remodeling complex is often regarded as tumor suppressors. SMARCA2 along with SMARCA4 is an ATPase of the complex. SMARCA2 might be post-translationally silenced in many cancers. The loss of this gene expression might be as a result of epigenetic or post-translational modifications and may not be due to gene mutation in pancreatic and lung cancer cell lines. The expression of SMARCA2 is regulated by histone deacetylases HDAC3 (Histone deacetylases) and HDAC9 (Histone deacetylases), along with transcription factors MEF2D (myocyte enhancer factor 2D) and GATA3 (GATA binding protein 3). Loss of both SMARCA2 and SMARCA4 is specifically observed in small cell carcinoma of the ovary hypercalcaemic type.. The expression of SMARCA2 is retained by histone deacetylase inhibitor trichostatin A. Nicolaides-Baraitser syndrome involves SMARCA2 mutation.

Características y beneficios

Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:
  • IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
  • Protein array of 364 human recombinant protein fragments.

Ligadura / enlace

Corresponding Antigen APREST86802

Forma física

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide.

Información legal

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Cláusula de descargo de responsabilidad

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Código de clase de almacenamiento

10 - Combustible liquids

Clase de riesgo para el agua (WGK)

WGK 1


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Shih-Chiang Huang et al.
PloS one, 16(1), e0245356-e0245356 (2021-01-23)
The clinicopathological significance of altered SWI/SNF complex has not been well evaluated in gastric cancer (GC). We examined SMARCA2, SMARCA4, SMARCB1 and ARID1A expression by immunohistochemistry in 1224 surgically resected GCs with subtyping into Epstein-Barr virus (EBV), microsatellite instability (MSI)
Petar Jelinic et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 29(1), 60-66 (2015-11-14)
Small cell carcinoma of the ovary, hypercalcemic type is an aggressive tumor generally affecting young women with limited treatment options. Mutations in SMARCA4, a catalytic subunit of the SWI/SNF chromatin remodeling complex, have recently been identified in nearly all small
Numerous BAF complex genes are mutated in Coffin-Siris syndrome.
Miyake N
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 166C(3), 257-261 (2014)
Immunohistochemistry successfully uncovers intratumoral heterogeneity and widespread co-losses of chromatin regulators in clear cell renal cell carcinoma
Jiang W, et al.
PLoS ONE, 11(10), e0164554-e0164554 (2016)
Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.
Jelinic P
Modern Pathology, 29(1), 60-66 (2016)

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico